文献速递皮肤肿瘤

第8版TNM分期及其对皮肤癌的意义:英国皮肤科医师协会与皇家病理学院综述

The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K.
PubMed 文献 · Br J Dermatol · 2018-09-05

第8版TNM分期相较第7版有多项重要变化,英国公共卫生署与皇家病理学院已采用该版进行皮肤癌分期。非黑色素瘤皮肤癌的T1-T3类别按最大径20毫米和40毫米划分,新风险因素可将T1或T2上调为T3;黑色素瘤pT1不再受核分裂指数影响,新增0.8毫米Breslow厚度分层;默克尔细胞癌的前哨淋巴结活检纳入pN分期。

要点

  • 非黑色素瘤皮肤癌(除外默克尔细胞癌)T1-T3按最大径20毫米和40毫米划分。
  • 黑色素瘤pT1不再受核分裂指数影响,新增0.8毫米Breslow厚度分层。
  • 默克尔细胞癌前哨淋巴结活检纳入pN分期,需注明淋巴结隐匿或临床可检出。

核心结论

  • 第8版TNM分期相较第7版有诸多重要变化,英国公共卫生署与皇家病理学院已采用该版进行皮肤癌分期。
  • 这些变化将影响黑色素瘤和非黑色素瘤皮肤癌的管理与委托配置。

研究设计与样本

  • 本文为英国皮肤科医师协会与皇家病理学院共同撰写的综述。
  • 原文未报告检索范围。

主要发现

  • 非黑色素瘤皮肤癌的T1-T3类别要求临床医生测量每个潜在浸润癌的最大径,鳞状、基底和附件癌按最大径20毫米和40毫米划分,默克尔细胞癌除外。
  • 新风险因素可将T1或T2上调为T3。
  • 黑色素瘤pT1分期不再受核分裂指数影响,新增0.8毫米Breslow厚度分层,pTa/b/c细分中pT1b伴前哨淋巴结活检阴性(pN0)现为IA期,而此前为IB期。
  • 默克尔细胞癌的前哨淋巴结活检现已具体纳入pN分期系统,pT1细分要求临床信息说明组织学受累淋巴结为临床隐匿或可检出。
  • 黑色素瘤和默克尔细胞癌均要求临床医生说明淋巴结为隐匿或临床可检出;眼睑癌继续采用与一般皮肤不同的分期系统,TNM8中该系统大幅修订。

关键数值与推荐

  • 非黑色素瘤皮肤癌(鳞状、基底和附件癌,不包括默克尔细胞癌)T1-T3按最大径20毫米和40毫米划分。
  • 黑色素瘤pT1新增0.8毫米Breslow厚度分层,pT1b伴pN0现为IA期(此前为IB期)。
  • 默克尔细胞癌前哨淋巴结活检纳入pN分期,pT1细分需临床信息说明淋巴结隐匿或可检出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 8th edition of TNM (tumour, node and metastasis) has numerous and important changes compared with the 7th edition. Public Health England and the Royal College of Pathologists, U.K., have adopted the 8th edition of TNM (TNM8) published by the Union for International Cancer Control for skin cancer staging. These changes will have an impact on the management and commissioning of melanoma and nonmelanoma skin cancer (NMSC). The T1-T3 categories for NMSC staging require the clinician to measure the maximum dimension (usually diameter) of every potential invasive cancer. For squamous, basal and adnexal carcinomas, but not Merkel cell carcinoma (MCC), the T1-T3 categories are defined by new 20-mm and 40-mm divisions based on the maximum dimension of the lesion. In addition, new risk factors upstage T1 or T2 to T3. For melanoma, mitotic index no longer influences separation of pathological stage (pT1). There is a new, additional stratification level at 0·8-mm Breslow thickness. Subdivision pT1b, with a negative sentinel lymph node biopsy (SLNB) of pN0, is now stage IA compared with the previous IB. For MCC, SLNB is now included specifically in the pN staging system. The pT1 subdivision requires clinical information as to whether histologically involved nodes were clinically occult or detectable. For both melanoma and MCC the clinician must state whether the lymph nodes are occult or clinically detectable. Eyelid carcinoma continues to have a staging system different from that in general skin and the system is substantially revised in TNM8.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Keohane SG, Proby CM, Newlands C, et al. The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K. Br J Dermatol. 2018. PMID: 29923189. doi:10.1111/bjd.16892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。